Entries |
Document | Title | Date |
20090111974 | Treatment of Liver Cirrhosis and Its Complications - The present invention relates to the field of liver diseases, more particularly to the field of portal hypertension and liver cirrhosis. The invention relates to the use of molecules which can inhibit the binding of placental growth factor (PIGF) to its receptor (VEGFR-1), such as monoclonal antibodies, for the manufacture of a medicament to treat liver cirrhosis, portal hypertension and its complications. | 04-30-2009 |
20090275737 | IMMUNOGENIC COMPOSITIONS AND USES THEREOF - The present invention relates generally to a method of eliciting or otherwise inducing an effective immune response to a micro-organism and compositions for use therein. More particularly, the present invention relates to a method of inducing an immune response to a parasite utilising an immunogenic composition comprising a glycosylphosphatidylinositol (referred to herein as “GPIt”) inositolglycan domain or its derivatives. Even more particularly, the present invention contemplates an immunogenic composition comprising the | 11-05-2009 |
20100010203 | ANTI-HYDROXYLASE ANTIBODIES AND USES THEREOF - Antibodies, or antigen-binding portions thereof, to aspartyl (asparaginyl) β-hydroxylase are provided. The anti-aspartyl (asparaginyl) β-hydroxylase antibodies, or antigen-binding portions thereof, can modulate activity of aspartyl (asparaginyl) β-hydroxylase. | 01-14-2010 |
20100041874 | HIGH THROUGHPUT METHODS FOR CHARACTERIZATION OF ANTIBODIES - The invention relates to methods for the characterization of monoclonal antibodies, in particular high throughput methods for the characterization of antibodies with respect to internalization and complement activation. | 02-18-2010 |
20100184960 | Antibodies Against Human IL-22 And Uses Therefor - The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders. | 07-22-2010 |
20100305307 | HUMAN MONOCLONAL ANTIBODIES TO EPIDERMAL GROWTH FACTOR RECEPTOR - In accordance with the present invention, there are provided fully human monoclonal antibodies against human epidermal growth factor receptor (EGF-r). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences from CDR1 through CDR3, are provided. Hybridomas expressing such immunoglobulin molecules and monoclonal antibodies are also provided. Also provided in accordance with the invention are antibodies that possess one or more of the following functional characteristics: (i) inhibit tyrosine phosphorylation of EGF-r, (ii) do not inhibit EGF-r internalization, (ii) inhibit EGF-r degradation, (iii) inhibition of EGF induced EGF-r degradation, (iv) protect threonine phosphorylation of EGF-r, (v) protect threonine phosphorylation of other molecules, particularly a 62 KD molecule identified by immunoprecipitation, and (vi) inhibit vascular endothelial cell growth factor signal by tumor cells by greater than 50% and endothelial cells by greater than 40% relative to control. | 12-02-2010 |
20110003974 | Modified fluorescent proteins and methods for using same - Embodiments of the present invention provide nucleic acid molecules encoding improved fluorescent mutants of the Katushka fluorescent protein, variants and derivatives thereof, as well as proteins and peptides encoded by these nucleic acids. Also of interest are proteins that are substantially similar to, or derivatives, or homologues, or mutants of, the above-referenced specific proteins. Also provided are fragments of the nucleic acids and the peptides encoded thereby, as well as antibodies specific to the proteins and peptides of the invention. In addition, host-cells, stable cell lines and transgenic organisms comprising the above-referenced nucleic acid molecules are provided. The subject protein and nucleic acid compositions find use in a variety of different applications and methods, particularly for labeling of biomolecules, cells or cell organelles. Finally, kits for use in such methods and applications are provided. | 01-06-2011 |
20110034677 | RECURRENT GENE FUSIONS IN PROSTATE CANCER - Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided. | 02-10-2011 |
20110054150 | Methods of Treating Inflammatory Pain - Methods of Treating Inflammatory Pain The invention relates to an anti-CGRP antibody for use in the prevention and/or treatment of inflammatory pain and/or symptoms of inflammatory pain, and to a method of treating and/or preventing inflammatory pain and/or symptoms of inflammatory pain using an anti-CGRP antibody. | 03-03-2011 |
20110065902 | HIGH AFFINITY HUMAN ANTIBODIES TO PCSK9 - An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements. | 03-17-2011 |
20110105733 | SINGLE VARIABLE DOMAINS AGAINST THE NOTCH PATHWAYS - The present invention relates to amino acid sequences (also referred to herein as “single variable domain(s) of the invention”. “Nanobody™ of the invention” or “Nanobodies™ of the invention”, ilpolypeptide(s) of the invention”) that are directed against (as defined herein) members of the Notch signalling pathway such as the four mammalian members of the Notch Receptors (Notch-1, Notch-2, Notch-3, Notch-4, hereinafter also “Notch Receptors”) and the five mammalian members of the Notch Ligands (the Delta-like family with “DLL1”, “DLL3”, “DLL4” wherein “DLL” stands for Delta-like ligand; the Jagged family with “Jagged-1”, “Jagged-2”, hereinafter also “Notch Ligands”), as well as to constructs that comprise or essentially consist of one or more such single variable domain(s) (also referred to herein as “construct of the invention” and “constructs of the invention”, “Nanobody™ of the invention” or “Nanobodies™ of the invention”, respectively). In particular, this invention relates to Notch pathway interfering single variable domains down- or up-regulating Notch signaling (also referred to herein “Notch-antagonists” or “Notch-agonists”). | 05-05-2011 |
20110118447 | METHODS AND MATERIALS FOR TARGETED AFFINITY ENHANCEMENT - The present disclosure relates to materials and methods for enhancing the binding affinity of antibodies by introducing a number of targeted amino acid changes in antibody variable domains. The present disclosure provides novel methods of flowcharted amino acid change cycles, of identifying residues as members of unique proximity groups and of determining the degree of conspicuousness of amino acid residues in antibody variable regions. The disclosed methods are useful for the selection of variable region amino acid residues that are candidates for change to produce antibody variable domains with enhanced affinity for their binding partners. | 05-19-2011 |
20110184154 | CELL BROTH CLARIFICATION AND HOST CELL PROTEIN REMOVAL - The present invention relates to a method for clarification of, and removal of host cell proteins from, a cell broth consisting essentially of viable cells, a culture medium and a secreted desired biological substance having an overall positive charge in the cell broth by contacting the cell broth with a particulate anion exchanger, allowing an adequate incubation time to result in formation of a cell pellet and a supernatant layer, separating the resulting cell pellet from the supernatant layer. The present invention further relates to a method for the recovery of a secreted desired biological substance from the cell broth by extracting the secreted desired biological substance from the supernatant layer. | 07-28-2011 |
20110245473 | Anti-IL-6 Receptor Antibody - The present inventors succeeded in discovering specific amino acid mutations in the variable region, framework region, and constant region of TOCILIZUMAB, and this enables to reduce immunogenicity risk and the heterogeneity originated from disulfide bonds in the hinge region, as well as to improve antigen binding activity, pharmacokinetics, stability under acidic conditions, and stability in high concentration preparations. | 10-06-2011 |
20110288278 | DIAGNOSTIC AGENT AND THERAPEUTIC AGENT FOR PANCREATIC CANCER - The present invention provides a novel diagnostic or therapeutic method for pancreatic cancer employing a blood marker. The present invention provides a diagnostic or therapeutic drug for pancreatic cancer containing an anti-AMIGO2 antibody. | 11-24-2011 |
20110313139 | METHOD FOR POLYCLONAL IMMUNOGLOBULIN G PRODUCTION BY HUMAN B CELLS - This application relates to an in vitro method of producing a polyclonal IgG preparation. The method comprises (i) placing a polyclonal B-cell population enriched in IgG-secreting B cells in a culture medium; and (ii) culturing the polyclonal B-cell population under conditions enabling the production of the polyclonal IgG preparation from the polyclonal B-cell population. This improved method enables the production of antibodies (preferably IgG) and facilitates long-term culture of polyclonal B-cell populations. | 12-22-2011 |
20120065381 | PROTEIN PURIFICATION - A method for purifying a polypeptide by ion exchange chromatography is described in which a gradient wash is used to resolve a polypeptide of interest from one or more contaminants. | 03-15-2012 |
20120071637 | SELECTIVE ENRICHMENT OF ANTIBODIES - The invention relates to a process for the selective concentration of immunoglobulins or other proteins that contain an Fc domain (target protein), comprising the following steps:
| 03-22-2012 |
20120238730 | INTEGRATED APPROACH TO THE ISOLATION AND PURIFICATION OF ANTIBODIES - Disclosed herein is an integrated approach to purification process development and execution, including processes comprising particular capture and fine purification steps; processes that employ of a minimal number of buffer systems, and processes that make use of minimally-corrosive buffer systems, as well as combinations thereof. | 09-20-2012 |
20120253020 | Compositions and Methods for Identifying Agents Which Modulate PTEN Function and PI-3 Kinase Pathways - Methods are provided for the identification, biochemical characterization and therapeutic use of agents which impact PTEN, p53, PI-kinase and AKT mediated cellular signaling. | 10-04-2012 |
20120283419 | Separation of protein monomers from aggregates by solid weak anion exchange support functionalized with amine moieties - A flow-through process for separating protein monomer from aggregates of that protein in a solution containing both protein monomer and aggregates of that protein, the process includes the steps of | 11-08-2012 |
20120309943 | ANTIBODY-IMMOBILIZED CARRIER, METHOD OF PRODUCING ANTIBODY-IMMOBILIZED CARRIER, AND USE OF SAID ANTIBODY-IMMOBILIZED CARRIER - The present invention provides an antibody-immobilized carrier that can be used in antibody screening, a method of producing the antibody-immobilized carrier, and use of the antibody-immobilized carrier. Efficient antibody screening can be carried out particularly by an antibody-immobilized carrier including two or more antibody immobilized regions onto each of which a heavy-chain low-molecular-weight antibody and a light-chain low-molecular-weight antibody are separately immobilized, the two or more antibody immobilized regions each being included in an independent manner, the heavy-chain low-molecular-weight antibody including a heavy-chain variable region, the light-chain low-molecular-weight antibody including a light-chain variable region, the heavy-chain low-molecular-weight antibody and the light-chain low-molecular-weight antibody each being derived from an antibody recognizing a different antigen. | 12-06-2012 |
20130079501 | ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) - Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described. | 03-28-2013 |
20130079502 | ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) - Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described. | 03-28-2013 |
20130090457 | Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases - Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed. | 04-11-2013 |
20130131323 | METHOD FOR STORAGE AND STABILIZATION OF A TARGET SUBSTANCE - The invention relates to a system and method for the stable storage of sensitive biological or chemical target substance, in a bound form on certain capture media. The method comprised providing a sample containing the target substance in a suitable buffer; combining the sample with a capture media to effect reversible binding of the target substance to the capture media; and storing the capture media with the target substance at between about −20 and 20° C.; and recovering the target substance from the capture media. The target substance recovered maintains the desired activity. Also provides are methods for reducing aggregates in the sensitive biological or chemical target substance. | 05-23-2013 |
20130150560 | AMYLOID BETA-DERIVED DIFFUSIBLE LIGANDS (ADDLs), ADDL-SURROGATES, ADDL-BINDING MOLECULES, AND USES THEREOF - The invention herein comprises amyloid beta-derived diffusible ligands (ADDLs), compositions comprising ADDLs, ADDL-surrogates, ADDL-binding molecules, and methods of using any of the foregoing compounds and compositions. ADDLs comprise amyloid β protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes. The invention also comprises methods of generating ADDL-specific antibodies and methods of using ADDL-specific antibodies for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as using such antibodies to detect compounds that block the formation or activity of ADDLs, and methods of identifying such compounds. The invention further provides methods of using ADDL-specific antibodies in modulating ADDL formation and/or activity, inter alia in the treatment of learning and/or memory disorders. | 06-13-2013 |
20130150561 | SINGLE-DOMAIN BRAIN-TARGETING ANTIBODY FRAGMENTS DERIVED FROM LLAMA ANTIBODIES - A phage-displayed library of llama single heavy domain antibodies (sdAbs) was enriched for species that selectively bind to and are internalized by human cerebromicrovascular endothelial cells (HCEC). From the enriched library, two sdAbs were selected, sequenced, subcloned, and expressed as fusion proteins with c-myc-His | 06-13-2013 |
20130178608 | PROTEIN PURIFICATION BY ION EXCHANGE - The application describes an antibody purification method comprising multiple chromatographic steps wherein the low pH eluate from a protein A chromatography is further purified without the need of substantial pH adjustment. | 07-11-2013 |
20130184441 | Detection of Neurodegenerative Disease - Provided are methods of assessing the absence or presence of a neurodegenerative disease in a subject comprising characterizing TDP-43 in a tissue sample of the subject. Also disclosed are methods for diagnosing a neurodegenerative disease in a subject, and methods for determining the efficacy of a drug against a neurodegenerative disease. Novel antibodies that bind to TDP-43 are also provided. | 07-18-2013 |
20130197201 | ANTIBODY LIBRARIES - The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. | 08-01-2013 |
20130217866 | OPTIMIZED METHOD FOR ANTIBODY CAPTURING BY MIXED MODE CHROMATOGRAPHY - Herein is reported a method for the purification of an antibody directly captured from clarified cell culture supernatants using Streamline CST and/or Capto MMC, wherein especially product related (aggregates and fragments) and process related impurities (host cell protein, media components) could efficiently be removed, resulting in a preparation with a purity comparable to classical protein A affinity chromatography. | 08-22-2013 |
20130281677 | MODIFIED ANTIBODY WITH IMPROVED HALF-LIFE - The present invention relates to antibodies, immunoglobulin constructs or immunoglobulin IgG4 fusion proteins whose in vivo half-lives are increased by the combination of (i) a modified IgG4 Fc region or FcRn binding domain thereof and (ii) a modified IgG4 hinge region sequence. | 10-24-2013 |
20130289249 | SIMPLIFIED ONE-POT SYNTHESIS OF [18F]SFB FOR RADIOLABELING - A non-aqueous single pot synthesis of [ | 10-31-2013 |
20130317203 | Anti-IL-6 Receptor Antibody - The present inventors succeeded in discovering specific amino acid mutations in the variable region, framework region, and constant region of TOCILIZUMAB, and this enables to reduce immunogenicity risk and the heterogeneity originated from disulfide bonds in the hinge region, as well as to improve antigen binding activity, pharmacokinetics, stability under acidic conditions, and stability in high concentration preparations. | 11-28-2013 |
20140128579 | SPECIFIC DELIVERY OF AGROCHEMICALS - Described is the specific delivery of agrochemicals to plants. More specifically, a targeting agent has at least one binding domain that specifically binds to a binding site on an intact living plant. Such binding domains include a peptide having 4 framework regions and 3 complementary determining regions, or fragment(s) thereof, wherein the binding domains bind or retain a carrier onto a plant. Described are binding domains that specifically bind trichomes, stomata, cuticle, lenticels, thorns, spines, root hairs, or wax layer. Further described are methods for delivering agrochemicals to a plant, for depositing agrochemicals on a plant, and for retaining the agrochemicals on a plant, using targeting agents comprising the binding domains, and to methods for protecting a plant against stress or controlling plant growth. Also, described are methods for manufacturing a specifically targeting agrochemical carrier. | 05-08-2014 |
20140206849 | ANTIBODIES HAVING REDUCED IMMUNOGENICITY IN A HUMAN - The disclosure relates to engineered antibodies that when administered to a human, exhibit a low level of immunogenicity in the human. The disclosure also relates to methods for generating the antibodies. The engineered antibodies can be derived from, e.g., on-human (e.g., murine) donor antibodies or from chimeric or humanized antibodies that, when chronically administered to a human, are known to, are predicted to, or are expected to, elicit a neutralizing anti-antibody response in the human. | 07-24-2014 |
20140309405 | METHOD OF PRODUCING HETEROGENEOUS PROTEIN - The present invention provides a method capable of producing a natural or recombinant protein in high yield. The present invention relates to a method of producing a polypeptide, comprising culturing a cell which strongly expresses alanine aminotransferase and has a transferred DNA encoding a desired polypeptide and thereby allowing the cell to produce the polypeptide. | 10-16-2014 |
20140336365 | CDR REGIONS OF MONOCLONAL ANTIBODY THAT ANTAGONIZE SPHINOGOSINE 1-PHOSPHATE AND RELATED METHODS - Materials and method for treating cancer and screening for anti-neoplastic agents are provided. These materials and methods can include sphingosine 1-phosphate antagonists that bind to sphingosine-1 phosphate receptor subtype 3. Antibodies and aptamers that selectively bind to an epitope in the extracellular loop between transmembrane domains two and three of sphingosine-1-phosphate receptor subtype 3 are provided. | 11-13-2014 |
20150018532 | ANTIBODY - The invention relates to antibodies to | 01-15-2015 |
20150133644 | METHOD TO PRODUCE AN IMMUNOGLOBULIN PREPARATION WITH IMPROVED YIELD - The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein. | 05-14-2015 |
20160017045 | EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY - Provided are an improved EGFR antibody or a functional segment thereof, comprising an engineered heavy chain and light chain. Specifically, the antibody is an engineered whole human-source monoclonal antibody. Also provided is a method for manufacturing said whole human-source antibody and usage of the antibody in the manufacture of medicines used for the treatment of tumors. | 01-21-2016 |